cancercell_bw_virus_edited_edited_edited.jpg

 T-SIGn Platform

®

Tumor-Specific Immuno-Gene Therapy (T-SIGn®) is a clinically validated, systemically-dosed, viral vector platform that enables tumor-localized production of immunotherapeutics that, in effect, turn cancer cells into “drug factories” that drive sustained reprogramming of the tumor microenvironment in both primary and metastatic tumor sites.

The exquisitely engineered T-SIGn® viral vectors deliver combinations of transgenes encoding protein therapeutics and synthetic payloads in a single product to target multiple mechanistic barriers within solid tumors.

 

The platform uses enadenotucirev, a blood-stable chimeric group B adenovirus, as a viral vector system for the delivery of therapeutic transgenes to cancer cells, taking advantage of the clinically demonstrated tumor selectivity and intravenous delivery properties of this virus. The platform is highly leverageable to many different therapies, targeting relevant mechanistic barriers to treatment.

 

T-SIGn® viral vectors can be specifically designed to act as a monotherapy or to work in synergy with other agents, such as cellular therapies, which are otherwise poorly effective in a solid tumor setting.

transgenearmedvector.png

1

Transgene Armed Vector Genome

MULTI-THERAPEUTIC FLEXIBILITY

Cytokines         Bispecifics
Chemokines    Synthetic Payloads
Antibodies        etc.

tsign.png

PROPRIETARY VECTOR SYSTEM

Allows up to five transgenes providing tumor-specific expression of novel payload combinations in one treatment modality

2

T-SIGn    Vector

® 

link.png

Standard of care or other

Immuno-Oncology Therapies

(e.g. CAR T-cell therapy)

imunooncology.png

3

Immuno-Oncology Candidate

IV DELIVERY

Targets primary and metastatic tumors

as a monotherapy or in combination

(e.g with CAR T-cell therapy)

Primary

Tumors

Metastic

Tumors

ivtherapy.png

Tumor-specific Replication

and Payload Production

  • Harness endogenous immunity

  • Express T cell chemo-attractants

  • Express cytokines, antibodies or other immunomodulators

  • Cell surface or spray-painted antigens

  • Activate and direct exogenous therapies

    • CAR-T/NK

TUMOR SHRINKAGE

4

cancer detail.png

Tumor Cells

 LOCAL

TRANSGENE

EXPRESSION

ACTIVATION OF

ANTI-TUMOR IMMUNITY

APC

T cell

The possibilities are endless.

Marrying our mastery of vector design with our deep expertise in immunology and biology of the tumor microenvironment opens a multitude of potential opportunities for innovative combination therapeutic approaches for treating cancer. 

In addition to conventional biologic molecules, such as antibodies, antibody fragments, bi-specifics, cytokines, chemokines and other immunomodulators, we are also exploring novel synthetic payload designs as we build an exciting and powerful pipeline of new T-SIGn® candidates, both independently and through partnership. 

The clinically demonstrated capability of our vectors to selectively produce their transgene payloads in tumor cells following intravenous infusion has enabled us to break free from the constraints hampering traditional oncolytic viruses, potentially enabling the treatment of patients with both primary and metastatic disease.

We are experts at designing vector constructs, and the payload opportunities are endless. Our T-SIGn® tumor re-programming technology extends beyond traditional oncolytic viruses and we are continuing to explore other novel synthetic payloads and ways of combining more agents to develop a powerful pipeline of new T-SIGn® opportunities. These can include antibody fragments, bispecifics, engagers, and other immune-modulators, rationally designed to target specific tumor indications.